BSE Live
Jan 21, 16:01Prev. Close
1166.90
Open Price
1167.65
Bid Price (Qty.)
1155.00 (2)
Offer Price (Qty.)
1155.50 (8)
NSE Live
Jan 21, 15:59Prev. Close
1166.70
Open Price
1170.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1157.20 (513)
| Key Financial Ratios of Dr Reddys Laboratories (in Rs. Cr.) | Mar 05 | |
| Per Share Ratios | ||
| Basic EPS (Rs.) | 4.30 | |
| Diluted EPS (Rs.) | 4.30 | |
| Cash EPS (Rs.) | 21.27 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 253.76 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 253.76 | |
| Revenue from Operations/Share (Rs.) | 240.62 | |
| PBDIT/Share (Rs.) | 19.64 | |
| PBIT/Share (Rs.) | 3.22 | |
| PBT/Share (Rs.) | 1.81 | |
| Net Profit/Share (Rs.) | 4.17 | |
| NP After MI And SOA / Share (Rs.) | 4.30 | |
| Profitability Ratios | ||
| PBDIT Margin (%) | 8.16 | |
| PBIT Margin (%) | 1.33 | |
| PBT Margin (%) | 0.75 | |
| Net Profit Margin (%) | 1.73 | |
| NP After MI And SOA Margin (%) | 1.78 | |
| Return on Networth/Equity (%) | 1.69 | |
| Return on Capital Employed (%) | 1.24 | |
| Return on Assets (%) | 1.12 | |
| Total Debt/Equity (X) | 0.14 | |
| Asset Turnover Ratio (%) | 0.00 | |
| Liquidity Ratios | ||
| Current Ratio (X) | 2.07 | |
| Quick Ratio (X) | 1.69 | |
| Inventory Turnover Ratio (X) | 0.00 | |
| Dividend Payout Ratio (NP) (%) | 116.24 | |
| Dividend Payout Ratio (CP) (%) | 23.36 | |
| Earnings Retention Ratio (%) | -16.24 | |
| Cash Earnings Retention Ratio (%) | 76.64 | |
| Coverage Ratios | ||
| Interest Coverage Ratios (%) | 13.90 | |
| Interest Coverage Ratios (Post Tax) (%) | 13.90 | |
| Valuation Ratios | ||
| Enterprise Value (Cr.) | 5,000.44 | |
| EV/Net Operating Revenue (X) | 2.72 | |
| EV/EBITDA (X) | 33.28 | |
| MarketCap/Net Operating Revenue (X) | 3.07 | |
| Retention Ratios (%) | -16.24 | |
| Price/BV (X) | 2.91 | |
| Price/Net Operating Revenue | 3.07 | |
| Earnings Yield | 0.01 |
22.01.2026
16.01.2026
15.12.2025
12.12.2025
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
28.10.2025
Dr Reddys Labs Consolidated September 2025 Net Sales at Rs 8,828.30 crore, up 9.83% Y-o-Y
28.10.2025
Dr Reddys Labs Standalone September 2025 Net Sales at Rs 4,618.60 crore, down 31.03% Y-o-Y
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
22.01.2025
Dr Reddy's Labs Q3 Preview: Lower Revlimid contribution, subdued US sales to dent earnings growth
12.07.2023
Dr Reddys Laboratories Q1 PAT seen up 73.7% YoY to Rs 912.4 cr: Nirmal Bang
24.01.2023
Dr Reddy’s Q3 Preview | Sharp drop in net profit likely on slump in US revenues
27.10.2022
Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz